Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jun;24(3):155-8.
doi: 10.3341/kjo.2010.24.3.155. Epub 2010 Jun 5.

The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy

Ji Won Lim  1 , Su Jeong Ryu, Min Cheol Shin
Affiliations
Randomized Controlled Trial

The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy

Ji Won Lim et al. Korean J Ophthalmol. 2010 Jun.

Abstract

Purpose: To evaluate the effect of intravitreal bevacizumab injection (IVBI) in acute central serous chorioretinopathy (CSC) patients.

Methods: Patients with acute CSC received IVBI (1.25 mg/0.05 mL) or observation by randomization. Twelve eyes in each group completed 6 months of regular follow-up and were ultimately included in this study. Each patient was assessed using best corrected visual acuity measurements, fluorescein angiography, and optical coherence tomography at baseline and had regular follow-ups after treatment.

Results: All patients showed improvements in visual acuity and fluorescein angiographic leakage and had resolution of their neurosensory detachment following treatment. There were no significant differences in visual acuity, central retinal thickness, or remission duration between the IVBI group and the control group at baseline or after treatment (p>0.05).

Conclusions: Intravitreal bevacizumab showed no positive effect in acute CSC patients compared to the observation group, and there were no adverse effects of treatment. Further investigation will be helpful to understand this therapy in patients with CSC.

Keywords: Bevacizumab; Central serous chorioretinopathy; Randomized comparison; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
(A) Graph showing serial changes in the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) for patients in the intravitreal bevacizumab injection (IVBI) group (solid line) and in the observation group (dashed line). Error bars represent standard errors of the mean. (B) Graph showing the serial changes in mean central macular thicknesses as measured using optical coherence tomography in the IVBI group (solid line) and in the observation group (dashed line). Error bars represent standard errors of the mean.
See this image and copyright information in PMC

References

    1. Gass JD. Pathogenesis of disciform detachment of neuroepithelium: II. Idiopathic central serous choroidopathy. Am J Ophthalmol. 1967;63:587–615. - PubMed
    1. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96:854–859. - PubMed
    1. Loo RH, Scott IU, Flynn HW, Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24. - PubMed
    1. Chan WM, Lai TY, Lai RY, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–1765. - PubMed
    1. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–145. - PubMed

Publication types

Substances

LinkOut - more resources